This article was originally published in The Gray Sheet
Cytyc extends purchase offer expiration date for Digene's outstanding shares to April 11 from March 28 after receiving formal request from FTC for additional information and documentary material concerning the proposed acquisition. Cytyc inked the $554 mil. deal in February (1"The Gray Sheet" Feb. 25, 2002, p. 3)...
You may also be interested in...
The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer
Sanofi’s sales grew strongly in the second quarter, driven by the immunologic Dupixent and its vaccines business, with the company also reporting success in a further potential indication for the product, chronic spontaneous urticaria. The big pharma has raised its EPS guidance for the year.
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.